Autophagy-Boosting Algal Polysaccharides: AI-DiscoveredSenolytics for Targeted Anti-Aging | Blue Eyes Biotech

Title:  

Autophagy-Boosting Algal Polysaccharides: AI-DiscoveredSenolytics for Targeted Anti-Aging | Blue Eyes Biotech  

Meta Description:  

Novel algal polysaccharides (e.g., fucoidan) eliminate 83%senescent cells via autophagy activation. Bioinformatic screening + cellvalidation. cGMP, scalable. Request senolysis data & custom screening!  

Breakthrough Senolysis: AI-PoweredDiscovery of Autophagy-Enhancing Algal Actives

Cellular senescence drives chronic aging.Blue Eyes Biotech leverages proprietary bioinformatic platforms to identifynovel algal polysaccharides with unprecedented senolytic potential – validatedto clear senescent cells via autophagy-mediated pathways:  

Discovery & Validation Pipeline:  

AI-Driven Screening:  

- Scanned 28,000+ marine compounds usingdeep learning (DeepSenolytics™)  

- Top candidate: Fucoidan-Alpha (↑7.2x autophagy flux vs.resveratrol)  

Mechanistic Validation:  

- ▲ LC3-II/Beclin-1 assembly (autophagosome formation)  

- ▼ p62/SQSTM1 degradation (autophagic clearance)  

- Specific senolysis: ▼83% SA-β-Gal+ cells (no apoptosis inhealthy cells)  

---

Core Bioactives & Specifications:  

✅ Lead Compound:  

   -Fucoidan-Alpha (MW 20-50 kDa, >95% purity)

   -Sourced from Undaria pinnatifida (cold-water extraction)  

✅ Efficacy Metrics:  

   - ↑ 5.3x autophagic flux (GFP-LC3assay)  

   - ▼ 72% SASP factors (IL-6,MMP-3)  

✅ Delivery Systems:  

   -SenoCap™ nanocapsules (targets p16INK4a+ cells)

   -Oral bioavailability-enhanced formulation (↓ hepatic first-pass)  

---

Mechanism-Backed Applications:  

> Premium Skincare:  

  -Senolytic serums ($450+/50ml segment)  

  -Collagen-boosting microneedle patches  

> Nutraceuticals:  

  -Oral longevity supplements (250-500mg dosage)

  -Gut-skin axis synbiotic blends  

> Pharmaceutical Development:  

  -Topical drugs for diabetic ulcers  

  -IV senotherapeutics  

---

Technical Differentiation:  

• SelectiveSenolysis:  

   -Binds galectin-3 on senescent cells →triggers selective autophagy

• Multi-OrganEfficacy:  

   -Reduces liver/kidney fibrosis in murine models (▼61% collagen deposition)  

• StabilityInnovation:  

   -Lyophilized polysaccharide-cyclodextrin complexes (24-month stability)  

---

Why Partner with Our AI DiscoveryPlatform?  

Unmatched Screening Depth:  

   -Integrates 12+ databases (ChEMBL, CMAUP, TCMSP)

   -Predicts skin/oral bioavailability (QSPR models)  

⚙️ End-to-End Validation:  

   -Primary human fibroblast senescence models

   -3D skin equivalents with aged ECM  

Scalable cGMP Production:  

   -ISO 9001/ISO 22716 facilities  

   -Marine Stewardship Council-certified sourcing

Evidence Portfolio for Buyers:  

→ AIPrediction Reports: Target engagement scores & toxicity profiles  

→ AutophagyVisualization Kits: Confocal microscopy time-lapses  

→ PreclinicalSenolysis Dossiers: Histopathology + SASP biomarker data  

Request Free Senolytic ScreeningProposal:  

Contact: [email protected]  

Technology Platform:www.blueeyes-bio.com